BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » CardioCell

FUJIFILM Expands Its Reign in Regenerative Medicine

September 8, 2016 By Cade Hildreth (CEO) Leave a Comment

FUJIFILM Expands Its Reign in Regenerative Medicine

It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]

Filed Under: iPS Cells, MSCs Tagged With: Axiogenesis, BrainXell, CardioCell, cynata, FUJIFILM

European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction

August 30, 2016 By Cade Hildreth (CEO) Leave a Comment

Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction (AMI)

Data Indicate Administering Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Intravenously Improves Cardiac Function Following an AMI

ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 29, 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study “Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and attenuate adverse remodeling in mice with large acute MI” at the European Society of Cardiology (ESC) Congress.

Paper Co-Author Dr. Michael Lipinski, ‎Interventional Cardiologist at MedStar Washington Hospital Center, presents the study that was designed in collaboration with Drs. Dror Luger, Research Scientist at Washington Hospital Center and Stephen Epstein, Director, Translational and Vascular Biology Research at MedStar Heart and Vascular Institute, Chair of CardioCell’s Scientific Advisory Board and Member of CardioCell’s Heart Failure Advisory Board. [Read more…]

Filed Under: Stem Cells Tagged With: CardioCell, Stemedica Cell Technologies

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

April 24, 2016 By Cade Hildreth (CEO) Leave a Comment

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

This was a major week in the stem cell sector, with significant announcements released by STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, and more. The FDA also released significant news pertaining to a public hearing that will  address the regulation of stem cells within the United States. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: Accellta, CardioCell, Cellect Biomed Ltd., STEMCELL Technologies

Enrollment Complete for CardioCell’s Phase IIa Chronic Heart Failure Trial Utilizing Ischemia-Tolerant MSCs

April 20, 2016 By Cade Hildreth (CEO) Leave a Comment

CardioCell Completes Enrollment for a Phase IIa Clinical Trial Using Its Stem Cells for Participants With Chronic Heart Failure - Depositphotos_76528209_m-2015.jpg

In major news released today, CardioCell, LLC, annnounced that it had completed enrollment for its Phase IIa chronic heart failure (HF) clinical trial.

The Phase IIa study protocol delivers ischemia-tolerant mesenchymal stem cells (itMSCs) via intravenous infusion to participants with non-ischemic cardiomyopathy. CardioCell’s  itMSCs are exclusively licensed from its parent company, Stemedica.

Complete details for the clinical trials can be viewed at: http://clinicaltrials.gov/ct2/show/NCT02123706.

To learn more, view the full press release issued by CardioCell, LLC, below. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: CardioCell, chronic heart failure, clinical trial, Stemedica

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.